WO2005009471A1 - Composition pour abaisser la glycemie - Google Patents
Composition pour abaisser la glycemie Download PDFInfo
- Publication number
- WO2005009471A1 WO2005009471A1 PCT/JP2004/011129 JP2004011129W WO2005009471A1 WO 2005009471 A1 WO2005009471 A1 WO 2005009471A1 JP 2004011129 W JP2004011129 W JP 2004011129W WO 2005009471 A1 WO2005009471 A1 WO 2005009471A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- histamine
- diabetic
- receptor
- blood sugar
- action
- Prior art date
Links
- 0 *C(OC(OC(C(Cc1c[n]cn1)NC(CCN)=O)=O)[Al])=O Chemical compound *C(OC(OC(C(Cc1c[n]cn1)NC(CCN)=O)=O)[Al])=O 0.000 description 4
- IYFXKBYFFAMCPV-UHFFFAOYSA-N CC(OC(C)=O)OC(C(Cc1c[nH]cn1)NC(CCN)=O)=O Chemical compound CC(OC(C)=O)OC(C(Cc1c[nH]cn1)NC(CCN)=O)=O IYFXKBYFFAMCPV-UHFFFAOYSA-N 0.000 description 2
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/4164—1,3-Diazoles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
- G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
- G01N2333/705—Assays involving receptors, cell surface antigens or cell surface determinants
- G01N2333/72—Assays involving receptors, cell surface antigens or cell surface determinants for hormones
- G01N2333/726—G protein coupled receptor, e.g. TSHR-thyrotropin-receptor, LH/hCG receptor, FSH
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2500/00—Screening for compounds of potential therapeutic value
- G01N2500/04—Screening involving studying the effect of compounds C directly on molecule A (e.g. C are potential ligands for a receptor A, or potential substrates for an enzyme A)
Definitions
- Fig. 1 shows the NMR spectrum obtained upon dissolving the TFA salt of imidazole compound (3) [ ⁇ -Ala-His-OCH 2 -OCO-C(CH 3 ) 3 ] prepared in Manufacturing Example 1 in deuterated methanol and carrying out 400 MHz NMR measurements.
- Fig. 2 is a graph indicating the hypoglycemic action of (R)-(-)- ⁇ -methylhistamine (MH) on the hyperglycemic response caused by intracerebral administration of 2-deoxy-D-glucose
- FIG. 9 is a figure indicating actual electric recordings based on the results of Fig. 8.
- preinjection indicates pre-administration (minute 0)
- post injection indicates the measured results 30 minutes post-administration.
- H3 agonist means (R)-(-)-a-methylhistamine.
- Fig. 10 is a graph indicating that the renal sympathetic nerve activity is lowered based on administration of the histamine H 3 receptor agonist (R)-(-)- ⁇ -methylhistamine (MH) into the abdominal aorta, and that the decrease is inhibited by addition of a histamine H 3 receptor antagonist (thioperamide: Thiop.) (Reference Experimental Example 3).
- histamine H 3 receptor which is present in the presynaptic membrane of histaminergic neuron cell and control the metabolic rotation of histamine neuron, deeply participate in the control (elevation and decrease) of blood sugar levels in the body, and further, that substances that exert an agonist or agonist-like action on the histamine H 3 receptor are effective for preventing or treating illnesses caused by hyperglycemia such as diabetes and complications thereof by controlling and improving the hyperglycemic state (lowering the blood sugar level of a hyperglycemic state). Furthermore, the present inventors developed novel imidazole compounds, and found the compounds improve a hyperglycemic state through histamine H 3 receptor.
- Item 36 The use according to any of Items 29 to 35, wherein the disease caused by hyperglycemia is type II diabetes or complications thereof.
- Item 37 A screening method for an active ingredient of a composition for lowering blood sugar comprising a step of, selecting from the test samples a substance having an action to suppress the release of histamine from the presynaptic membrane of histaminergi ⁇ neuron cell, directly or indirectly using the amount of histamine released from the presynaptic membranes as an indicator.
- Item 38 A screening method for an active ingredient of a composition for lowering blood sugar comprising a step of, selecting from the test samples a substance having an action to suppress the release of histamine from the presynaptic membrane of histaminergi ⁇ neuron cell, directly or indirectly using the amount of histamine released from the presynaptic membranes as an indicator.
- the screening method for active ingredients of a composition for lowering blood sugar comprising the steps of: (a) administering a test substance to test animals with hyperglycemia artificially induced, and measuring the changes of blood sugar levels before and after administration; (b) selecting a substance that has an action to improve a hyperglycemic state artificially induced (hypoglycemic action) based on the results obtained in step (b); and if necessary, (c) selecting from substances selected in step (b) a substance whose th action to improve the hyperglycemic state artificially induced is inhibited by a histamine H 3 receptor * antagonist.
- Item 41 comprising the steps of: (a) administering a test substance to test animals with hyperglycemia artificially induced, and measuring the changes of blood sugar levels before and after administration; (b) selecting a substance that has an action to improve a hyperglycemic state artificially induced (hypoglycemic action) based on the results obtained in step (b); and if necessary, (
- the screening method according to Item 41 comprising the steps of: (a) directly or indirectly measuring whether a test substance reacts with histamine H 3 receptor to suppress release of histamine; (b) for the substance for which the action to suppress release of histarnines has been confirmed in said step (a), directly or indirectly measuring whether that action to suppress release of histarnines is inhibited by histamine H 3 receptor antagonists; and (c) selecting a substance whose the action to suppress release of histarnines is inhibited by the histamine H 3 receptor antagonist.
- the screening method according to Item 42 comprising a step of conducting a binding assay of the test substance with histamine H 3 receptor, and selecting a histamine H 3 receptor agonist.
- the screening method comprising the steps of: (a) administering a test substance to test animals with hypergl ⁇ cemia artificially induced, and measuring the changes of blood sugar levels before and after administration; (b) selecting a substance that has an action to improve a hyperglycemic state artificially induced (hypoglycemic action) based on the results obtained in step (a) ; and if necessary, (c) selecting from substances selected in step (b) a substance whose the action to improve the hyperglycemic state artificially induced is inhibited by a histamine H 3 receptor antagonist.
- Item 45 comprising the steps of: (a) administering a test substance to test animals with hypergl ⁇ cemia artificially induced, and measuring the changes of blood sugar levels before and after administration; (b) selecting a substance that has an action to improve a hyperglycemic state artificially induced (hypoglycemic action) based on the results obtained in step (a) ; and if necessary, (c) selecting from substances selected in step
- composition to lower blood sugar of the present invention has a substance, as an active ingredient, that exerts a direct or indirect stimulus action on the histamine H 3 receptor present in the brain, particularly in the hypothalamus, and more specifically in the presynaptic membrane of the histaminergic neuron cells in the brain.
- Pharmaceutical compositions or food compositions may be cited as suitable compositions to lower blood sugar.
- Substance that exert a direct or indirect stimulus action on the histamine H 3 receptor (sometimes, called simply "H 3 receptor stimulant" hereinafter) may be used singly as the hypoglycemic agent, but preferably, any carriers or additives acceptable for medicines or foods may be combined as components other than the substance, and used as compositions to lower blood sugar.
- salts examples include salts with inorganic acid (for example, hydrochloric acid, phosphoric acid, hydrobromi ⁇ acid, sulfuric acid, hydra ⁇ id), or salts with organic acids (for example, acetic acid, formic acid, propionic acid, fumaric acid, maleic acid, succinic acid, tartari ⁇ acid, citric acid, malic acid, oxalic acid, benzoic acid, methansulfonic acid, benezenesulfonic acid) .
- the H 3 receptor stimulants targeted by the present invention also include hydrates, hydrated salts or substances having polycrystalline structures.
- the modified form may be, for example: a substance that has a modified form that is not metabolized in the digestive tract or blood, and that becomes the H 3 receptor stimulant in the brain after passing through the blood-brain barrier; or a substance that has a modified form that easily passes through the blood- brain barrier, and that becomes the H 3 receptor stimulant in the brain after passing through the blood-brain barrier.
- Solid dosing forms such as tablets, pills, bulk drug, powder, granules and capsules, etc.
- liquid dosing forms such as solutions, suspensions, emulsions, syrups, and elixirs, etc.
- external dosing forms such as patches, ointments, creams and sprays.
- carriers to formulate these pharmaceutical preparations include fillers, diluents, binders, moisturizers, disintegrators, disintegration inhibitors, absorption promoters, lubricants, dissolution supplements, solubilizing agents, buffers, emulsifiers, and suspending agents.
- the amount of active ingredient to be contained in the aforementioned pharmaceutical composition and the dosage thereof is not particul rly limited, and may be suitably selected in a range corresponding to the desired therapeutic effect, administration method, therapy period, age of the patient, sex, and other conditions.
- the dosage varies depending on the dosing route, but may be suitably selected in the range of approximately 0.1 pg to 1 mg/60 kg by calculating the amount of active ingredient per dose in relation to a person weighing 60 kg. Preferably, this is approximately 0.2 pg to 200 ⁇ g/60 kg.
- Imidazole compound (2) can then be obtained by removing the protecting groups therefrom. Note that the preparation of the 1-iodoethyl acetate can be carried out referring to the document [Y. Yoshimura et al. , J. Antibiotics, 39, 1329 (1986)].
- imidazole compound (5) [ ⁇ -Ala-His- OCH(CH 3 )OCOOCH(CH 3 ) 2 ] and imidazole compound (6) [ ⁇ -Ala-His- OCH(CH 3 )OCOOC 6 H ] can be obtained using a similar method to imidazole compound (4) [ ⁇ -Ala-His-OCH 2 -OCO-OCH 2 CH 3 *2HCl] (Manufacturing Example 2). That is, the corresponding alkyl 1- chloroethyl carbonate and sodium iodide are reacted together to obtain the alkyl 1-iodoethyl carbonate.
- the form of the unit of administration of the pharmaceutical composition can be variously selected as appropriate in accordance with the route of administration; such forms ca ⁇ > be broadly categorized into orally administered preparations] nasally administered preparations, vaginally administered preparations, suppositories, sublingual preparations, non-orally administered preparations (injections, drips), external preparations (patches, ointments, creams, sprays) and so on.
- aCSF means the results when artificial cerebrospinal fluid (test sample (1)) was independently administered in the lateral ventricle of the test rats;
- 2DG-aCSF means the results by administrating of 2DG solution (containing aCSF) (test sample (2));
- 2DG-MH means the results by administrating of a mixed solution of 2DG solution and MH solution (including aCSF) (test sample (3));
- 2DG-MH- Thiop means the results by administrating of a mixed solution of 2DG solution, MH solution, and thioperamide solution (including aCSF) (test sample (4)).
- Group 2 100 ⁇ L of FMH solution (100 mg/kg/saline 100 ⁇ L) was intraperitoneally administered, and 100 ⁇ L of FMH solution (100 mg/kg/saline 100 ⁇ L) was re-administered 22 hours later. Two hours later, 20 ⁇ L of 2DG solution (40 ⁇ mol/aCSF 20 ⁇ L) was intracerebrally administered.
- histamine Hi receptor antagonists also inhibit the hyperglycemic response caused by 2DG (provisional model of a hyperglycemic response during hypoglycemic conditions) .
- 2DG provisional model of a hyperglycemic response during hypoglycemic conditions
- histamine neurons and histamine Hi receptor in the brain participate in maintenance of homeostasis in the body (regulation of the autonomic nervous system) related to blood sugar levels.
- histamine neurons have a function to stimulate sympathetic nerves and suppress the activity of the parasympathetic nerves by the release of histarnines mediated though histamine Hi receptor.
- mice were divided in 4 groups based on the "random blood sugar level" [group 1: control group (not administered immepip); group 2: immepip 0.05 mg/kg dosing group; group 3: immepip 0.5 mg/kg dosing group; and group 4: immepip 5.0 mg/kg dosing group], and from the following day (7 weeks of age), immepip hydrobromide (TpcrisCooksonlnc. , USA) was repeatedly administered subcutaneously once per day for 7 days (dose administered 2 mL/kg) .
- immepip hydrobromide TpcrisCooksonlnc. , USA
- a cerebral cannula made of PE-10 (Clay Adams, Parsippany, NJ) was inserted into the right lateral cerebral ventricle (LCV)
- a cardiac catheter comprising a Silastic tube (Dow Corning, Midland MI) and a PE-50 tube (Clay Adams, Parsippany, NJ) was inserted into the right atrium of the heart.
- the rats were divided into three groups (group 1: 5 rats, group 2: 5 rats, group 3: 3 rats), and various samples were administered to the respective groups of rats using the method described below.
- hypoglycemic agent agent to suppress elevated blood sugar, hypoglycemic agent
- agent for preventing or treating any of various disorders caused by hyperglycemia diabetes, complications of diabetes
- the present invention provides novel imidazole compounds. As shown in the Experimental Example, such an imidazole compound has an action of reducing the blood sugar level of subjects (rats in the Experimental Example) in a hyperglycemic state.
Landscapes
- Health & Medical Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Diabetes (AREA)
- Medicinal Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- General Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Engineering & Computer Science (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Emergency Medicine (AREA)
- Endocrinology (AREA)
- Hematology (AREA)
- Obesity (AREA)
- Epidemiology (AREA)
- Investigating Or Analysing Biological Materials (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Abstract
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP2006519248A JP2007528860A (ja) | 2003-07-28 | 2004-07-28 | 血糖降下用組成物 |
Applications Claiming Priority (4)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US49063603P | 2003-07-28 | 2003-07-28 | |
US60/490,636 | 2003-07-28 | ||
US55461904P | 2004-03-19 | 2004-03-19 | |
US60/554,619 | 2004-03-19 |
Publications (1)
Publication Number | Publication Date |
---|---|
WO2005009471A1 true WO2005009471A1 (fr) | 2005-02-03 |
Family
ID=34107872
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/JP2004/011129 WO2005009471A1 (fr) | 2003-07-28 | 2004-07-28 | Composition pour abaisser la glycemie |
Country Status (2)
Country | Link |
---|---|
JP (1) | JP2007528860A (fr) |
WO (1) | WO2005009471A1 (fr) |
Cited By (7)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US8829041B2 (en) | 2006-06-23 | 2014-09-09 | Abbvie Inc. | Cyclopropyl amine derivatives |
US8853390B2 (en) | 2010-09-16 | 2014-10-07 | Abbvie Inc. | Processes for preparing 1,2-substituted cyclopropyl derivatives |
US8932201B2 (en) | 2006-07-25 | 2015-01-13 | Ams Research Corporation | Surgical articles and methods for treating pelvic conditions |
US9108948B2 (en) | 2006-06-23 | 2015-08-18 | Abbvie Inc. | Cyclopropyl amine derivatives |
US9186353B2 (en) | 2009-04-27 | 2015-11-17 | Abbvie Inc. | Treatment of osteoarthritis pain |
CN106365998A (zh) * | 2016-08-19 | 2017-02-01 | 陕西思尔生物科技有限公司 | 一种特戊酸碘甲酯的制备方法 |
WO2023285790A1 (fr) * | 2021-07-15 | 2023-01-19 | Nottingham Trent University | Analogues de carnosine destinés à être utilisés dans le traitement de troubles métaboliques |
Families Citing this family (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
KR101858113B1 (ko) | 2016-11-28 | 2018-05-15 | 건국대학교 글로컬산학협력단 | 실리비닌을 유효성분으로 함유하는 케토시스 예방 및 치료용 약학 조성물. |
Citations (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2000053596A2 (fr) * | 1999-03-08 | 2000-09-14 | Schering Corporation | Composes imidazole substitues par un noyau heterocyclique a six ou sept membres renfermant deux atomes d'azote |
WO2001068651A1 (fr) * | 2000-03-17 | 2001-09-20 | Novo Nordisk A/S | Imidazoles condenses comme ligands du recepteur h3 de l'histamine |
WO2001068652A1 (fr) * | 2000-03-17 | 2001-09-20 | Novo Nordisk A/S | Imidazoles condenses en tant que ligands de recepteur d'histamine h3 |
EP1297830A1 (fr) * | 2001-09-28 | 2003-04-02 | Flamma Fabbrica Lombarda Ammino Acidi S.p.a. | L'utilisation des acides aminés alpha ou bèta, leurs esters, ou de dipeptides de ces acides aminés avec des dérivés d'histidine, dans la prévention ou le traitement de lésions de la peau causées par l'ozone atmosphérique |
WO2003059342A1 (fr) * | 2002-01-11 | 2003-07-24 | Abbott Laboratories | Ligands de recepteur d'histamine-3 pour traiter des etats diabetiques |
-
2004
- 2004-07-28 WO PCT/JP2004/011129 patent/WO2005009471A1/fr active Application Filing
- 2004-07-28 JP JP2006519248A patent/JP2007528860A/ja active Pending
Patent Citations (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2000053596A2 (fr) * | 1999-03-08 | 2000-09-14 | Schering Corporation | Composes imidazole substitues par un noyau heterocyclique a six ou sept membres renfermant deux atomes d'azote |
WO2001068651A1 (fr) * | 2000-03-17 | 2001-09-20 | Novo Nordisk A/S | Imidazoles condenses comme ligands du recepteur h3 de l'histamine |
WO2001068652A1 (fr) * | 2000-03-17 | 2001-09-20 | Novo Nordisk A/S | Imidazoles condenses en tant que ligands de recepteur d'histamine h3 |
EP1297830A1 (fr) * | 2001-09-28 | 2003-04-02 | Flamma Fabbrica Lombarda Ammino Acidi S.p.a. | L'utilisation des acides aminés alpha ou bèta, leurs esters, ou de dipeptides de ces acides aminés avec des dérivés d'histidine, dans la prévention ou le traitement de lésions de la peau causées par l'ozone atmosphérique |
WO2003059342A1 (fr) * | 2002-01-11 | 2003-07-24 | Abbott Laboratories | Ligands de recepteur d'histamine-3 pour traiter des etats diabetiques |
Non-Patent Citations (2)
Title |
---|
YAMANO TOSHIHIKO ET AL.: "Effect of L-carnosin on tbe hyperglycemia caused by intracranial injection of 2-deoxy-D-glucose in rats", NEUROSCIENCE LETTERS, vol. 313, 2001, pages 78 - 82, XP002982975 * |
YOSHIMATSU HIRONOBU ET AL.: "Abnormalities in Obese Zuckers: Defective Control of Histaminergic Functions", PHYSIOLOGY & BEHAVIOR, vol. 54, no. 3, 1993, pages 487 - 491, XP002982976 * |
Cited By (8)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US8829041B2 (en) | 2006-06-23 | 2014-09-09 | Abbvie Inc. | Cyclopropyl amine derivatives |
US9108948B2 (en) | 2006-06-23 | 2015-08-18 | Abbvie Inc. | Cyclopropyl amine derivatives |
US8932201B2 (en) | 2006-07-25 | 2015-01-13 | Ams Research Corporation | Surgical articles and methods for treating pelvic conditions |
US9186353B2 (en) | 2009-04-27 | 2015-11-17 | Abbvie Inc. | Treatment of osteoarthritis pain |
US8853390B2 (en) | 2010-09-16 | 2014-10-07 | Abbvie Inc. | Processes for preparing 1,2-substituted cyclopropyl derivatives |
CN106365998A (zh) * | 2016-08-19 | 2017-02-01 | 陕西思尔生物科技有限公司 | 一种特戊酸碘甲酯的制备方法 |
WO2023285790A1 (fr) * | 2021-07-15 | 2023-01-19 | Nottingham Trent University | Analogues de carnosine destinés à être utilisés dans le traitement de troubles métaboliques |
GB2609002A (en) * | 2021-07-15 | 2023-01-25 | Univ Nottingham Trent | Carnosine Analogs |
Also Published As
Publication number | Publication date |
---|---|
JP2007528860A (ja) | 2007-10-18 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
EP3132792B1 (fr) | Composition et procédés d'augmentation de la sensibilité d'insuline | |
US11241429B2 (en) | Method of treating metabolic disorders and depression with dopamine receptor agonists | |
EP1811991B1 (fr) | Traitement du diabete de type 2 en utilisant d'inhibiteurs de la synthese des glycosphingolipides | |
Haynes et al. | Anorectic, thermogenic and anti-obesity activity of a selective orexin-1 receptor antagonist in ob/ob mice | |
CN1960735B (zh) | 药物组合在治疗胰岛素抗性中的应用 | |
US20230285328A1 (en) | Methods and Compositions for the Treatment of Steatosis-Associated Disorders | |
Shah et al. | GPR119 agonists for the potential treatment of type 2 diabetes and related metabolic disorders | |
Lee et al. | Intracerebroventricular injection of metformin induces anorexia in rats | |
WO2005009471A1 (fr) | Composition pour abaisser la glycemie | |
US20230256051A1 (en) | Modified kisspeptin receptor agonists for fatty liver disease | |
KR100590818B1 (ko) | 소분자 유기화합물의 직접적 p90 리보솜 S6 키나제 1(RSK1)의 활성증진에 의한 당뇨병, 비만 및대사증후군의 예방 및 치료용도 | |
KR100697097B1 (ko) | 당뇨병 예방 또는 치료용 약학 조성물 | |
Mulani | Effect Of Topiramate On Body Weight, Systolic Blood Pressure And Spontaneous Motor Activity In Olanzapine Treated Rats | |
WO2014057408A1 (fr) | Procédés pour augmenter la sensibilité à l'insuline avec des agonistes des récepteurs sérotoninergiques 5-ht2 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
AK | Designated states |
Kind code of ref document: A1 Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BW BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE EG ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NA NI NO NZ OM PG PH PL PT RO RU SC SD SE SG SK SL SY TJ TM TN TR TT TZ UA UG US UZ VC VN YU ZA ZM ZW |
|
AL | Designated countries for regional patents |
Kind code of ref document: A1 Designated state(s): BW GH GM KE LS MW MZ NA SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IT LU MC NL PL PT RO SE SI SK TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG |
|
121 | Ep: the epo has been informed by wipo that ep was designated in this application | ||
WWE | Wipo information: entry into national phase |
Ref document number: 2006519248 Country of ref document: JP |
|
122 | Ep: pct application non-entry in european phase |